摘要
神经医学最近出现在研究领域中,其在治疗方法中显示了有趣的挑战。由于多剂量药物的必要性、中枢神经系统的低药物浓度和副作用,通常用来治疗神经系统疾病的方法局限在他们的疗效和患者依从性程度方面。而且,治疗方法需要个体化的标准的药物剂量。神经医学方面的限制性障碍依然是阻止大脑内源性和外源性化合物聚集的血脑屏障。位于血脑屏障的多种转运蛋白可以调节内源性化合物的通过。研究发现,这些转运蛋白可以作为运输治疗剂和大分子的通路,使其通过血脑屏障,允许多种活性物质被吸收进入中枢神经系统。为了发展多类型的纳米医学,近期我们进行了多种尝试,使其能够克服常规疗法的局限性—首要的是通过血脑屏障。一个非常有前景的选择可能是胶状超分子聚集体的应用。这些纳米药物是安全、可生物降解和生物相容的;可以结合生物材料用于诊断和治疗应用。利用单克隆抗体、蛋白质、多肽和大分子可以使他们得到改良;因此提供个性化的神经医学使其用于治疗多种神经障碍。本文中,我们讨论了神经医学的超分子胶状载体的近期进展,尤其专注于它的最新发展。
关键词: 胶状纳米载体,药物投递系统,神经医学,超分子聚集体,超分子化学,治疗方法
Current Medicinal Chemistry
Title:Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Volume: 21 Issue: 36
Author(s): Donato Cosco, Luisa Di Marzio, Carlotta Marianecci, Elena Trapasso, Donatella Paolino, Christian Celia, Maria Carafa and Massimo Fresta
Affiliation:
关键词: 胶状纳米载体,药物投递系统,神经医学,超分子聚集体,超分子化学,治疗方法
摘要: Neuromedicine has recently been emerging on the research scene and presents interesting challenges in therapeutics. The range of therapies generally used to treat neurological disorders are limited in their efficacy and degree of patient compliance because of the necessity of multiple drug dosages, low drug concentration in the central nervous system and side effects. Moreover, therapeutics require standard drug dosages which cannot be personalized. The limiting obstacle in neuromedicine is still the blood-brain barrier, which prevents the accumulation of endogenous and exogenous compounds inside the brain. Various transporters located on the blood-brain barrier modulate the crossing of endogenous compounds. It has been discovered that these transporters can be used as pathways for the transport of therapeutic agents and macromolecules that pass the blood-brain barrier allowing the uptake of bioactive compounds into the central nervous system. Several attempts have recently been made to develop forms of nanomedicine capable of overcoming the limitations of conventional therapy, above all the crossing of the blood-brain barrier. An outstandingly promising option could be the use of colloidal supramolecular aggregates. These nanodrugs are safe, biodegradable, and biocompatible and can combine biomaterials useful for diagnostic and therapeutical applications. They can be modified using monoclonal antibodies, proteins, peptides and macromolecules, thus providing personalized neuromedicine, which can be used in the treatment of various neurological disorders. In this review, recent advancements of supramolecular colloidal devices as neuromedicines are discussed, with particular focus on the latest developments.
Export Options
About this article
Cite this article as:
Cosco Donato, Marzio Di Luisa, Marianecci Carlotta, Trapasso Elena, Paolino Donatella, Celia Christian, Carafa Maria and Fresta Massimo, Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine, Current Medicinal Chemistry 2014; 21 (36) . https://dx.doi.org/10.2174/0929867321666140826113933
DOI https://dx.doi.org/10.2174/0929867321666140826113933 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Osteoinductive Small Molecules: Growth Factor Alternatives for Bone Tissue Engineering
Current Pharmaceutical Design In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Current Research on Opioid Receptor Function
Current Drug Targets Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design Nucleic Acid Aptamers Against Protein Kinases
Current Medicinal Chemistry Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Evaluation of Cytotoxic Potentials of Some Isoindole-1, 3-Dione Derivatives on HeLa, C6 and A549 Cancer Cell Lines
Medicinal Chemistry Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology The Heterogeneity of Glioma Stem Cells
Current Signal Transduction Therapy Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology PET and SPECT Imaging for the Acceleration of Anti-Cancer Drug Development
Current Drug Targets